Company intelligence / Profile preview

Amy Reichelt

Toronto, Ontario, Canadaamyreichelt.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PurMinds has an active clinical pipeline developing small molecules, psychedelic compounds, and other modalities targeting neurological/neurodegenerative disorders. Their Ontario facility holds a Health Canada license for production of pharma-grade psilocybin and MDMA for research/clinical trials. They are pursuing both short/mid-term revenue paths alongside long-term value creation through accelerated novel therapeutic development.

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: Small moleculePsychedelic compoundPsychoplastogen
Industry: Biotech

Beyond the preview

Go deeper on Amy Reichelt.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amy Reichelt.

Explore the full profile